Study of immune cells in blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of one of these blood cancers: polycythemia vera (PV), essential thrombocythemia (ET), pre-myelofibrosis, or primary myelofibrosis.
- You should not have started any treatment for your blood cancer at the time your blood sample is collected.
- You must be 18 years old or older and able to give your consent.
- You must agree to have your blood sample stored in a research database (FIMBANK).
- You cannot have any other blood cancer or active cancer at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This is an observational study that follows people with certain blood disorders. It aims to learn more about how these conditions behave in real life, which can help improve future care.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.